About
About
About
About
About
Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.
Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.
Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.
Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.
Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.
A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.
A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.
A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.
A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.
A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.
Leadership Team
Leadership Team
Leadership Team
Leadership Team
Leadership Team
CEO
Alex Batchelor
View bio
CEO
Alex Batchelor
View bio
CEO
Alex Batchelor
View bio
CEO
Alex Batchelor
View bio
CEO
Alex Batchelor
View bio
Scientific Co-Founder
Nicolas Shiaelis
View bio
Scientific Co-Founder
Nicolas Shiaelis
View bio
Scientific Co-Founder
Nicolas Shiaelis
View bio
Scientific Co-Founder
Nicolas Shiaelis
View bio
Scientific Co-Founder
Nicolas Shiaelis
View bio
Scientific Co-Founder
Dr. Nicole Robb
View bio
Scientific Co-Founder
Dr. Nicole Robb
View bio
Scientific Co-Founder
Dr. Nicole Robb
View bio
Scientific Co-Founder
Dr. Nicole Robb
View bio
Scientific Co-Founder
Dr. Nicole Robb
View bio
CFO
Tom Amies
View bio
CFO
Tom Amies
View bio
CFO
Tom Amies
View bio
CFO
Tom Amies
View bio
CFO
Tom Amies
View bio
Chief Business Officer
Chris Stampfl
View bio
Chief Business Officer
Chris Stampfl
View bio
Chief Business Officer
Chris Stampfl
View bio
Chief Business Officer
Chris Stampfl
View bio
Chief Business Officer
Chris Stampfl
View bio
Advisors
Advisors
Advisors
Advisors
Advisors
Rachel Gauntlett
View bio
Rachel Gauntlett
View bio
Rachel Gauntlett
View bio
Rachel Gauntlett
View bio
Rachel Gauntlett
View bio
Dr. Rishi Chopra
View bio
Dr. Rishi Chopra
View bio
Dr. Rishi Chopra
View bio
Dr. Rishi Chopra
View bio
Dr. Rishi Chopra
View bio
Dr Richard Dawood
View bio
Dr Richard Dawood
View bio
Dr Richard Dawood
View bio
Dr Richard Dawood
View bio
Dr Richard Dawood
View bio
Professor Miles Caroll
View bio
Professor Miles Caroll
View bio
Professor Miles Caroll
View bio
Professor Miles Caroll
View bio
Professor Miles Caroll
View bio
Dr. Iain Miller
View bio
Dr. Iain Miller
View bio
Dr. Iain Miller
View bio
Dr. Iain Miller
View bio
Dr. Iain Miller
View bio
Our Investors
Our Investors
Our Investors
Our Investors
Our Investors
Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.
Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.
Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.
Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.
Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.
While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.
Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.
The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.
With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.
While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.
Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.
The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.
With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.
While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.
Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.
The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.
With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.
While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.
Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.
The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.
With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.
While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.
Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.
The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.
With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.
Request investor pack
Request investor pack
Request investor pack
Request investor pack
Request investor pack
Traction
Started Jan 2023 → ongoing: Clinical Trial
Novel Technologies for Respiratory Virus Identification (ResVir) [NCT05661032]
Our first clinical study is being conducted in partnership with the Queen Alexandra Hospital in Portsmouth, England. This is our first large-scale sample collection initiative where we aim to generate a large respiratory pathogen dataset on which we are continuously training PIC-ID Identify.
Read more
Aug 2023: Innovate UK SMART Grant
Our project culminated in the completion of our first prototype instrument in late 2022 providing proof of principle for an end-to-end automated workflow from cartridge insertion to test result.
November 2023: US Subsidiary Established
Key territory for Pictura, we opened a subsidiary office in the US to ensure market access as our technology develops.
February 2024: Defence and Security Accelerator Contract Completed
We recently completed a contract with the UK Defense and Security Accelerator (DASA) successfully building a ruggedized automated system and detected bacteria for the first time, with all engineering components contained within a portable case.
June 2025: Innovate UK Investor Partnership Project
Our latest Innovate UK funded project will allow us to continue development of our device to an alpha prototype. This includes size reduction of the VISTA Reader to a commercially acceptable size, whilst simultaneously improving PIC-ID Capture and training PIC-ID Identify. We anticipate the project will be completed by mid 2025.
June 2025 - VISTA Alpha
Our first near market ready system will be ready for broader testing with key partners and small scale manufacturing
July 2026 - VISTA Beta
Our system will be ready for clinical trials, broader adoption, as well as scaled-up manufacturing.